Use of bisphosphonates among women and risk of atrial-fibrillation and flutter: population based case-control study
Use of bisphosphonates among women and risk of atrial-fibrillation and flutter: population based case-control study
复制标题
DOI：
10.1136/bmj.39507.551644.be
复制
发表时间：
2008-04-01
影响因子：
105.7
通讯作者：
Baron, John A.
中科院分区：
文献类型：
--
作者：
Sorensen, Henrik Toft;Christensen, Steffen;Baron, John A.
目的评估房颤和扑动与使用双膦酸盐治疗妇女骨质疏松症之间的关系。设计基于人群的病例对照研究，使用来自丹麦的医学数据库。设置丹麦北方。参与者13586例房颤和扑动患者和68054例对照人群，所有患者均具有完整的住院史和处方史。主要结局指标：调整房颤和房扑的相对风险。结果435例患者（3.2%）和1958例人群对照（2.9%）是目前使用双膦酸盐治疗骨质疏松症的患者。依替膦酸盐和阿仑膦酸盐的使用频率在病例组和对照组中几乎相同。目前使用双膦酸盐与未使用相比的调整后相对风险为0.95（95%置信区间01.84至1.07）。新使用者的相对风险为0.75（0.49至1.16），与持续使用者的估计值大致相似（相对风险0.96，95%置信区间0.85至1.09）。相对风险估计是独立的处方数量和位置的心房颤动和扑动的诊断在出院record.Conclusion的住院患者和门诊患者是相似的，没有证据表明，使用双膦酸盐增加心房颤动和扑动的风险。
Objective To assess the association between atrial fibrillation and flutter and use of bisphosphonates for osteoporosis among women.Design Population based case-control study, using medical databases from Denmark.Setting Northern Denmark.Participants 13 586 patients with atrial fibrillation and flutter and 68 054 population controls, all with complete hospital and prescription history.Main outcome measure Adjusted relative risk of atrial fibrillation and flutter.Results 435 cases (3.2%) and 1958 population controls (2.9%) were current users of bisphosphonates for osteoporosis. Etidronate and alendronate were used with almost the same frequency among cases and controls. The adjusted relative risk of current use of bisphosphonates compared with non-use was 0.95 (95% confidence interval 01.84 to 1.07). New users had a relative risk of 0.75 (0.49 to 1.16), broadly similar to the estimate for continuing users (relative risk 0.96, 95% confidence interval 0.85 to 1.09). The relative risk estimates were independent of number of prescriptions and the position of the atrial fibrillation and flutter diagnosis in the discharge record, and were similar for inpatients and outpatients.Conclusion No evidence was found that use of bisphosphonates increases the risk of atrial fibrillation and flutter.